Claims for Patent: 7,704,947

Summary for Patent: 7,704,947

Title:	Methods and compositions for the treatment of gastrointestinal disorders
Abstract:	The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
Inventor(s):	Currie; Mark G. (Sterling, MA), Mahajan-Miklos; Shalina (Stanford, CA), Norman; Thea (San Diego, CA), Milne; G. Todd (Brookline, MA)
Assignee:	Ironwood Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:	11/930,696
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,704,947
Patent Claims:	1. A polypeptide comprising the amino acid sequence Cys Cys Glu Xaa Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr wherein Xaa is selected from Phe, Trp or Tyr (SEQ ID NO: 125) or a pharmaceutically acceptable salt thereof. 2. The polypeptide of claim 1 consisting of the amino acid sequence Cys Cys Glu Xaa Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr wherein Xaa is selected from Phe, Trp or Tyr (SEQ ID NO:125). 3. The polypeptide according to claim 1, which is purified. 4. The polypeptide according to claim 2, which is purified. 5. The polypeptide of claim 1 comprising the amino acid sequence Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 105) or a pharmaceutically acceptable salt thereof. 6. The polypeptide of claim 5 consisting of the amino acid sequence Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:105). 7. The polypeptide of claim 5 or a pharmaceutically acceptable salt thereof, wherein the polypeptide activates the guanylate cyclase C receptor. 8. A pharmaceutical composition comprising the polypeptide of claim 5 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient. 9. The polypeptide of claim 1 comprising the amino acid sequence Cys Cys Glu Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 109) or a pharmaceutically acceptable salt thereof. 10. The polypeptide of claim 9 consisting of the amino acid sequence Cys Cys Glu Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 109). 11. The polypeptide of claim 9 or a pharmaceutically acceptable salt thereof, wherein the polypeptide activates the guanylate cyclase C receptor. 12. A pharmaceutical composition comprising the polypeptide of claim 9 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient. 13. A pharmaceutical composition comprising the polypeptide of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient. 14. A pharmaceutical composition comprising the polypeptide of claim 2 and a pharmaceutically acceptable carrier or excipient. 15. A pharmaceutical composition comprising the polypeptide of claim 6 and a pharmaceutically acceptable carrier or excipient. 16. A pharmaceutical composition comprising the polypeptide of claim 10 and a pharmaceutically acceptable carrier or excipient.